Trial Profile
Effect of ombitasvir/paritaprevir/ritonavir ±dasabuvir on bile acid levels in patients with chronic hepatitis-C genotype1-4 infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 03 Dec 2018 New trial record